149 related articles for article (PubMed ID: 2972741)
1. Production of and response to interleukin-2 in Graves' disease.
Eisenstein Z; Engelsman E; Weiss M; Kalechman Y; Sredni B
J Clin Immunol; 1988 Sep; 8(5):349-55. PubMed ID: 2972741
[TBL] [Abstract][Full Text] [Related]
2. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the IL-2 production defect in vitro in Graves' disease.
Eisenstein Z; Engelsman E; Weiss M; Kalechman Y; Sredni B
Clin Exp Immunol; 1994 May; 96(2):323-8. PubMed ID: 8187341
[TBL] [Abstract][Full Text] [Related]
4. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
[TBL] [Abstract][Full Text] [Related]
5. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
6. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
7. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
8. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
Kallner G; Vitols S; Ljunggren JG
J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
[TBL] [Abstract][Full Text] [Related]
9. Alterations of Global DNA Methylation and DNA Methyltransferase Expression in T and B Lymphocytes from Patients with Newly Diagnosed Autoimmune Thyroid Diseases After Treatment: A Follow-Up Study.
Guo Q; Wu D; Yu H; Bao J; Peng S; Shan Z; Guan H; Teng W
Thyroid; 2018 Mar; 28(3):377-385. PubMed ID: 29336230
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
11. Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease.
Akuzawa M; Murakami M; Yamada M; Satoh T; Shimizu H; Mori M
Eur J Endocrinol; 1998 Mar; 138(3):281-5. PubMed ID: 9539302
[TBL] [Abstract][Full Text] [Related]
12. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease.
Tötterman TH; Karlsson FA; Bengtsson M; Mendel-Hartvig I
N Engl J Med; 1987 Jan; 316(1):15-22. PubMed ID: 2946953
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
Brokken LJ; Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
[TBL] [Abstract][Full Text] [Related]
15. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
16. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
[TBL] [Abstract][Full Text] [Related]
17. Reduction in the suppressor-inducer T cell subset and increase in the helper T cell subset in thyroid tissue from patients with Graves' disease.
Ishikawa N; Eguchi K; Otsubo T; Ueki Y; Fukuda T; Tezuka H; Matsunaga M; Kawabe Y; Shimomura C; Izumi M
J Clin Endocrinol Metab; 1987 Jul; 65(1):17-23. PubMed ID: 2953751
[TBL] [Abstract][Full Text] [Related]
18. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
Buerklin EM; Schimmel M; Utiger RD
J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
[TBL] [Abstract][Full Text] [Related]
19. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
